Report #2827335

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: GA
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	944942	IM / RA

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Received First Dose of Heplisav-B, and Second Dose Recombivax; Initial report received on 03-Feb-2025. A nurse reported that a female received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization, then one month later received a dose of RECOMBIVAX. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 944942, expiration date 31-Jan-2027, and NDC number 43528-003-05)] intramuscularly in the right deltoid. On an unknown date, one month after receiving HEPLISAV-B, the patient received a dose of a hepatitis B vaccine [RECOMBIVAX (lot number and expiration date not reported)]. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Recombivax hb